Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Policy / Regulatory

China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149

Fineline Cube May 14, 2026
Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Fineline Cube May 14, 2026
Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Fineline Cube May 14, 2026
Company R&D

Hainan Boao Lecheng Partners with BeiGene to Boost Medical Tourism and Biotech Innovation

Fineline Cube Aug 1, 2023

The Hainan Boao Lecheng International Medical Tourism Pilot Zone has entered into a partnership with...

Company Drug

Jiangsu Hengrui’s Camrelizumab and Apatinib Combo Accepted for FDA Review for HCC Treatment

Fineline Cube Aug 1, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that the US Food and Drug...

Company Drug

Jacobio Pharma’s Glecirasib Enters Breakthrough Therapy Review for Pancreatic Cancer Treatment

Fineline Cube Aug 1, 2023

China-based Jacobio Pharma (HKG: 1167) has announced that its novel KRAS G12C inhibitor, glecirasib, has...

Company Drug

Jiangsu Aidea’s ACC008 Demonstrates Non-Inferior Efficacy to Genvoya in Phase III HIV Study

Fineline Cube Aug 1, 2023

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced the summary report of a Phase...

Company Drug

Everest Medicines Completes Enrollment for Nefecon’s Phase III Extension Study in China

Fineline Cube Aug 1, 2023

China-based Everest Medicines (HKG: 1952) has announced the completion of patient enrollment for the China...

Company

WuXi AppTec Reports 6.28% Revenue Growth and 23.67% Net Profit Increase in H1 2023

Fineline Cube Aug 1, 2023

China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its financial report for...

Company

HutchMed Ltd Reports 164% Revenue Growth and Clinical Updates for H1 2023

Fineline Cube Aug 1, 2023

China-based HutchMed Ltd (NASDAQ: HCM; HKG: 0013) has announced its unaudited financial results for the...

Policy / Regulatory

Shanghai HSA Unveils Measures to Boost Access to Innovative Drugs and Devices

Fineline Cube Aug 1, 2023

The Healthcare Security Administration (HSA) in Shanghai has recently released a set of Measures aimed...

Company

Akeso Biopharma Reports First Positive Earnings in H1 2023 Financial Results

Fineline Cube Jul 31, 2023

Akeso Biopharma (HKG: 9926) has released its financial report for the first half of 2023,...

Company Medical Device

MicroPort MedBot’s SkyWalker Orthopedic Surgery Robot Gains TGA Approval in Australia

Fineline Cube Jul 31, 2023

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing...

Policy / Regulatory

CDE Releases Draft Guidelines for Clinical Pharmacology Research of Chemical Modified Drugs

Fineline Cube Jul 31, 2023

The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for Clinical Pharmacological Research...

Company Deals

Baidu Health Partners with GSK for Shingles Disease Education Programs in China

Fineline Cube Jul 31, 2023

China Internet giant Baidu’s Health Internet Hospital unit has entered into a strategic partnership with...

Company Drug

Transcenta Holdings Gets CDE Approval for Phase II Study of TST002 for Bone Density

Fineline Cube Jul 31, 2023

China-based biotech company Transcenta Holdings Ltd (HKG: 6628) has announced that it has received approval...

Company Drug

Zelgen Biopharmaceuticals’ ZG006 Earns NMPA Approval for Clinical Trials in Solid Tumors

Fineline Cube Jul 31, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a China-based biopharmaceutical company, has announced that it...

Company Deals

Mabwell Secures Licensing Deal with Morocco’s Sothema for Biosimilar Humira

Fineline Cube Jul 31, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a significant licensing and commercialization...

Company Drug

Shanghai Benemae’s Benaglutide Approved by NMPA for Adult Weight Management in China

Fineline Cube Jul 31, 2023

The National Medical Products Administration (NMPA) has indicated on its website that benaglutide, developed by...

Company Drug

Nanjing Leads Biolabs’ LBL-034 Secures Clinical Trial Approvals from NMPA and FDA

Fineline Cube Jul 31, 2023

Nanjing Leads Biolabs Co., Ltd, a China-based biopharmaceutical company, has announced receiving clinical trial approvals...

Company Deals

Sanofi to Boost CHC Unit with Full Acquisition of US Health Brand Qunol

Fineline Cube Jul 31, 2023

France-based pharmaceutical giant Sanofi (NASDAQ: SNY) has revealed that it has signed an agreement to...

Company Deals

AstraZeneca’s Alexion Secures Gene Therapy Portfolio in Deal with Pfizer

Fineline Cube Jul 31, 2023

AstraZeneca’s rare disease unit, Alexion (AZ, NASDAQ: AZN), has signed a significant purchase and license...

Company

AstraZeneca’s H1 2023 Financials Show 4% YOY Revenue Growth, Oncology and R&I Drive Sales

Fineline Cube Jul 31, 2023

UK-based pharmaceutical giant AstraZeneca plc (AZ, NASDAQ: AZN) has announced its financial results for the...

Posts pagination

1 … 495 496 497 … 666

Recent updates

  • Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors
  • Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad
  • Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement
  • Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors
  • Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Company Medical Device

Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad

Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.